Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Classement en actions #17309
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Prix de l'action
$1.21
Capitalisation boursière
$248.41M
Changement (1 jour)
4.11%
Changement (1 an)
79.12%
Pays
TW
Échange TWi Biotechnology, Inc. (6610)

Catégorie

EPS pour TWi Biotechnology, Inc. (6610)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de TWi Biotechnology, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de TWi Biotechnology, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH